All In Biotech

Drugs by condition

Drugs approved for achondroplasia

Brand-name prescription drugs and biologics whose FDA label lists achondroplasia as an approved use. Matched on the label phrases: "achondroplasia".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

2

Still marketed, NDA or BLA

Drug classes

1

Novel drugs

2

New molecular entities and new biologics

In development

6

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for achondroplasia.

  • Yuviwel (Navepegritide) · Ascendis NovelAccelerated approvalPriority reviewOrphanFeb 27, 2026
  • Voxzogo (Vosoritide) · Biomarin Pharm NovelAccelerated approvalOrphanNov 19, 2021

All approved drugs for achondroplasia, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 0 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Class not listed in FDA's data (2)

  • Yuviwel Navepegritide · Ascendis · 2026
  • Voxzogo Vosoritide · Biomarin Pharm · 2021

Drugs in development for achondroplasia

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline

More on achondroplasia: recruiting trials · published research

Related in rare and genetic disease: Transthyretin amyloidosis · Hereditary angioedema · Fabry disease · Gaucher disease · Pompe disease · Phenylketonuria (PKU)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.